A new study from Griffith University suggests that semaglutide, the key ingredient in the drugs Ozempic and Wegovy, may help lower the risk of psychiatric hospitalization for people with bipolar disorder. The research, published in Acta Psychiatrica Scandinavica, looked at nearly 15,000 individuals in Sweden who had bipolar disorder and were prescribed GLP-1 receptor agonists (GLP-1RAs) over 15 years. It found that those who used semaglutide had a 21% lower risk of being hospitalized for psychiatric reasons compared to times when they were not on these medications. GLP-1 receptor agonists are a class of drugs typically used to treat type 2 diabetes and obesity. They work by mimicking a hormone called GLP-1, which helps regulate blood sugar and appetite. The study suggests that semaglutide, in particular, may influence biological processes linked to inflammation and brain function, which could help stabilize mood in people with bipolar disorder. However, other GLP-1 drugs, such as liraglutide and dulaglutide, did not show similar mental health benefits in the study. The research was led by Professor Mark Taylor from Griffith University’s School of Medicine and Dentistry. He noted that this study adds to a growing body of evidence indicating that GLP-1 receptor agonists may offer benefits beyond managing diabetes and obesity. These drugs are now being explored for their potential role in mental health conditions, including bipolar disorder. While the findings are promising, the researchers emphasize the need for further study. They suggest that randomized controlled trials are necessary to confirm whether semaglutide can effectively improve psychiatric outcomes for people with bipolar disorder. This could open the door to new treatment options that address both physical and mental health needs.